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Abstract
Background:  Charcot-Marie-Tooth neuropathies are a group of genetically heterogeneous
diseases of the peripheral nervous system. Mutations in the MFN2 gene have been reported as the
primary cause of Charcot-Marie-Tooth disease type 2A.
Methods: Patients with the clinical diagnosis of Charcot-Marie-Tooth type 2 were screened using
single strand conformation polymorphism (SSCP). All DNA samples showing band shifts in the
SSCP analysis were amplified from genomic DNA and cycle sequenced.
Results: We analyzed a total of 73 unrelated patients with a clinical diagnosis of CMT 2. Overall,
novel mutations were detected in 6 patients. c.380G>T (G127V), c.1128G>A (M376I), c.1040A>T
(E347V), c.1403G>A (R468H), c.2113G>A (V705I), and c.2258_2259insT (L753fs).
Conclusion:  We confirmed a significant role of mutations in MFN2  in the pathogenesis of
Charcot-Marie-Tooth disease type 2.
Background
Charcot-Marie-Tooth neuropathies (CMT), also named as
hereditary motor and sensory neuropathies (HMSN) are a
group of genetically heterogeneous diseases of the periph-
eral nervous system. CMT has been classified into two
major subgroups. A severe reduction of nerve conduction
velocities (NCV) with NCV < 38 m/s is found in the demy-
elinating CMT type 1. The axonal type (CMT type 2) is
characterized by preferential degeneration of the axon
showing amplitude reductions in nerve conduction stud-
ies but only mildly reduced NCV. Both CMT1 and CMT2
have been recognized to be genetically heterogeneous.
Several genetic loci have been defined for both clinical
types. CMT2A was located to chromosome 1p35–p36 [1-
3]. Although a mutation in KIF1B was published in a large
CMT2A family, no further mutations were detected in
other families with CMT2A [4,5]. Züchner et al. identified
the MFN2 gene by means of linkage studies and reported
mutations in MFN2 in seven large families with linkage to
the CMT2A locus [5]. Recently, other groups confirmed
the MFN2 gene as the primary cause of CMT2A [6-8]. We
screened 73 unrelated patients with the clinical diagnosis
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of CMT2 and identified six new disease-causing muta-
tions.
Methods
Subjects
We analyzed samples of 73 unrelated patients sent to our
diagnostic laboratory with the request of genetic analysis
for Charcot-Marie-Tooth disease. Linkage analysis was not
possible in these individuals. Inclusion criteria for the
MFN2  analysis were a clinical classification of CMT2,
nerve conduction velocity (NCV) > 38 m/s, or histological
findings of axonal degeneration. EDTA blood samples
were taken from patients after informed consent. DNA
was extracted from blood leukocytes by standard meth-
ods. All control samples used to check the distribution of
sequence alterations mentioned in the results sections
were taken from an anonymous collective of ethnically
matched samples.
Mutation analysis of MFN2 gene
For mutation analysis in MFN2, primers were designed to
amplify all exons including flanking intronic regions.
Primer sequences are available on request. Exon 7 and 8,
and exon 10 and 11, respectively, were each amplified in
one amplicon including the intermediate intron. PCRs
were performed in 96-well microtiter plates (Thermowell
Costar Corning, NY) using a thermocycler (Biometra,
Goettingen, Germany). Each well contained 50 ng DNA in
10 μl reaction volume, GC buffer (Genecraft, Münster,
Germany), 10 pMol of forward and reverse primer, 1 U
Taq Polymerase (Genecraft, Münster, Germany), 2 mMol
of each dNTP, and a MgCl2 concentration of 1 mM. For
SSCP analysis, 0.06 μl of [α32 P] dCTP (10 mCi/ml) was
included in the PCR. PCR conditions included initial
denaturation (2 min at 94°C), two initial cycles at 94°C
(15 s) and 6°C and 3°C above the main annealing tem-
perature (30 s) followed by 30 s at 72°C, and 28–32 cycles
of 94°C (15 s), annealing temperature (30 s) and final
elongation step at 72°C (30 s). Annealing temperature
was 62°C except for exons 7/8, 10/11, 15, 16, 17, and 8
(58°C). PCR products were digested with suitable restric-
tion enzymes depending on the fragment size to optimize
the mutation detection rate by SSCP analysis. In the SSCP
analysis the denatured PCR products were separated by
polyacrylamide (PAA) gel electrophoresis using two dif-
ferent conditions: 30% PAA (acrylamide/bisacrylamide:
19/1) gel, 1xTBE, and either 10% glycerol or 5% glycerol/
1 M urea. Electrophoresis was carried out at 55 W for 3–4
h at 4°C. Gels were evaluated by autoradiography or
exposure to a phosphoimager screen, using the corre-
sponding software. Exon 13 was screened using SSCP and
DHPLC. DNA samples showing band shifts in the SSCP
analysis were amplified from genomic DNA and cycle
sequenced by standard protocols using the Megabace
1000 (Amersham Bioscience, Freiburg, Germany). If pos-
sible, restriction analysis with a suitable restriction
enzyme was applied to confirm the mutation and to ana-
lyse control samples. Enzymes were ordered from New
England Biolabs if not indicated otherwise.
Results
We analyzed a total of 73 unrelated patients with a clinical
diagnosis of CMT 2. Overall, novel mutations were
detected in 6 patients. The clinical features and the neuro-
graphical data of these patients are summarized (tables 1
and 2). Nerve biopsy has not been performed in any of
these 6 patients.
The heterozygous point mutation c.380 G>T in exon 5 of
MFN2  (fig. 1a) was detected in a 58 year old female
patient (patient 1), predicting the exchange of Glycine to
Valine at position 127 of the MFN2 protein (G127V). The
mutation leads to a loss of a recognition site for the restric-
tion enzyme Msc I, which was used to exclude this muta-
tion in 97 control persons (194 control chromosomes).
Clinically the patient shows a predominant axonal neu-
ropathy with normal motor nerve conduction velocity
(mNCV) in electrophysiological studies of the median
nerve. The family history is compatible with autosomal-
dominant inheritance, but other family members were
not available for genetic analysis.
Patient 2, a 34 year old male, is heterozygous for the point
mutation c.1128G>A in exon 11, predicting the exchange
of Methionine to Isoleucine at position 376 (M376I) (fig.
1b). This mutation is detectable by a loss of a NlaIII
restriction site, and was excluded by restriction analysis in
190 control chromosomes. The patient has distal sensory
loss in his legs, absent Achilles' tendon reflexes, pes cavus
and severely reduced amplitudes of the compound motor
nerve action potentials of the peroneal and tibial nerves,
but preserved motor nerve conduction velocities. His
mother, one brother and one sister reportedly have simi-
lar symptoms of peripheral neuropathy but denied further
neurophysiological testing or genetic analysis.
The point mutation c.1040A>T in exon 11, leading to the
exchange of Glutamine to Valine at position 347 (E347V)
of the protein, was detected in a 32 year old male (fig. 1c,
patient 3). The mutation was not observed by SSCP anal-
ysis in over 200 control chromosomes, detection by
restriction analysis was not possible. The parents of the
patient were reported to be healthy and unrelated, there is
no history of peripheral neuropathies in the family. The
patient has distal atrophy of his legs since childhood. He
also shows high-grade paresis of peroneus muscles in
both legs, severe pain in both legs and distal sensory loss.
Electrophysiological studies indicate an axonal neuropa-
thy with mildly decreased mNCV.BMC Medical Genetics 2006, 7:53 http://www.biomedcentral.com/1471-2350/7/53
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Patient 4, a 27 year old female, presented the mutation
c.1403G>A in exon 14 (fig. 1d). The mutation leads to the
exchange of Arginine to Histidine (R468H). Clinically the
patient shows distal weakness and atrophy of the legs, dis-
tal sensory loss and decreased mNCV. Her father has Par-
kinson disease and distal neuropathy. Her paternal
grandfather had pes cavus. Her sister and her mother both
do not present any symptoms of neuropathy. Mutation
analysis in the parents by restriction with AciI and by
sequencing proved the same mutation in her father, indi-
Table 2: Nerve conduction study in patients with CMT associated with mutation in MFN2
N o r m a l 123456
Motor
Median nerve
DML (ms) ≤ 3,9 2,8 3 3,8 5
NCV (m/s) ≥ 50 53 50 n.d. 46,2 56 n.d.
Amplitude (mV) ≥ 6 11,4 14,2 n.d. 11
Peroneal nerve
DML (ms) ≤ 4,8 7,6 4 5,3
NCV (m/s) ≥ 42 37 45 not 
recordable
47,8 not 
recordable
not 
recordable
Amplitude (mV) ≥ 4 0,8 8,4 2
Tibial nerve
DML (ms) ≤ 5,1 6,2 4,2 7,1
NCV (m/s) ≥ 41 31 36 38 n.d. not 
recordable
not 
recordable
Amplitude (mV) ≥ 5 0,6 0,4 0,4
Sensory
Median nerve
NCV (m/s) ≥ 47 60 54 n.d. 57,7 45 n.d.
Amplitude (mV) ≥ 7 13,4 11 n.d. 20
Sural nerve
NCV (m/s) ≥ 41 34 not 
recordable
30 56,5 32 not 
recordable
Amplitude (mV) ≥ 10 7,2 1 n.d. 6
DML= distal motor latency; NCV = nerve conduction velocity; n.d. = not determined.
Table 1: Clinical features of patients with MFN2 mutation
123456
Age (y)/sex 58/F 34/F 32/M 27/F 44/F 65/M
Onset age (y) 48 22 childhood 26 6 62
Initial 
symptoms
weakness in LE muscle crampi in 
LE
- paraesthesia in LE foot deformities gait ataxia
Motor
UE 0000 2 + 0
LE 2+ 2+ 2+ 2+ 3+ 2+
Sensory
pain/touch 1+ 1+ 0 0 2+ 2+
deep sense 2+ 1+ - 1+ 2+ 2+
Reflexes normal in UE, 
decreased (knee), 
absent (ankle)
normal in UE, 
absent (knee, 
ankle)
normal in UE, 
absent (ankle)
normal in UE, 
absent (knee, 
ankle)
decreased in UE, 
absent (knee, 
ankle)
normal in UE, 
absent (knee, 
ankle)
Pes cavus/varus y e sy e sy e sy e sy e sy e s
0, 1+, 2+, and 3+ = no, minimal, moderate, and severe involvement for muscle weakness and sensory deficit; – = no precise data. UE = upper 
extremities, LE = lower extremities.BMC Medical Genetics 2006, 7:53 http://www.biomedcentral.com/1471-2350/7/53
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cating cosegregation. However, the mutation was also
detected in one of 260 control chromosomes.
A 44 year old female patient (patient 5) with symptoms of
peripheral neuropathy since the age of six was found to
carry a point mutation c.2113G>A in exon 18 (fig. 1e)
leading to the exchange of Valine to Isoleucine at position
705 (V705I). No mutation was found in 212 control chro-
mosomes by restriction digest with HinI (Fermentas). Her
deceased father and her brother were reported to have
similar symptoms, but family members were not available
for genetic analysis. Patient 5 shows distal weakness and
atrophy of the lower and upper extremities. She has drop
feet and steppage gait, absent Achilles' tendon reflexes,
distal sensory loss of the lower extremities and decreased
sensitivity to vibration of both ankles.
Patient 6 carries a frameshift mutation (c.2258_2259insT
(L753fs)) in exon 19 (fig. 1f). This frameshift mutation
causes a change of the last four amino acids of the open
reading frame and leads to an extension of five new amino
acids at the end of the protein. By restriction analysis of
exon 19 with the enzyme PstI, this mutation was not
observed in 200 control chromosomes. Molecular genetic
analysis was carried out for this patient at the age of 73
years. There is no family history of peripheral neuropathy
but he was analyzed under suspect of CMT2 because of
symmetric distal weakness and increased distal paresis of
the legs.
Discussion
We detected MFN2  mutations in 6 patients out of 73
patients with a clinical diagnosis of axonal CMT2, indicat-
ing a rate of 8% similar to the findings around 10% up to
20% observed by other groups. None of these mutations
has been previously published, and (except the mutation
c.1403G→ A in patient 4) none of these has been found
in unrelated controls.
Our data confirm the findings of dominant mutations in
the  MFN2  gene to be associated with CMT2A [5].
Recently, mutations in MFN2 have also been linked to
two rare forms of hereditary neuropathy, namely HMSN V
(with pyramidal signs) [8] and HMSN VI (with optic atro-
phy) [9]. Our patients with mutations in MFN2  have
axonal polyneuropathy without additional symptoms.
Severity of symptoms is relatively mild and the rate of
clinical progression slow.
Although there are several hints linking peripheral neu-
ropathies to the mitochondrial network, the function of
mitofusins in peripheral nerves and also the role of MFN2
Electropherograms showing novel mutations in the MFN2 gene detected in this analysis Figure 1
Electropherograms showing novel mutations in the MFN2 gene detected in this analysis. Numbering of nucleotides is according 
to the open reading frame of the cDNA sequence as deposited in GenBank (GenBank accession no. BC017061).
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mutations in the pathogenesis of peripheral neuropathy is
only partly understood.
Mitochondria are active organelles forming a single
dynamic network whose continuity is maintained by a
balance of fission and fusion events [10]. In both yeast
and drosophila, mitochondrial fusion is controlled by the
nuclear-encoded mitochondrial transmembrane GTPase
fuzzy onions (Fzo) [11-13]. In humans and mice MFN2
and MFN1, two human homologues of Fzo exist and both
are essential for embryonic development and mitochon-
drial fusion [13]. MFN2 is the second HMSN disease gene
directly involved in the maintenance of the mitochondrial
network. In contrast to mitofusins, overexpression of gan-
glioside-induced differentiation associated protein 1
(GDAP1) is interfering with mitochondrial fusion and
induces fragmentation of mitochondria, and recessive
mutations in GDAP1 have been found in patients with
CMT4A [14,15].
MFN2 is localized to the outer mitochondrial membrane.
The protein contains two coiled-coil regions flanking a
transmembrane segment and a GTPase domain. Func-
tional coiled-coil regions are essential for tethering of
mitochondria before fusion [16-18]. An intact GTPase
domain is indispensable for the function of mitofusins
[12,17,19]. Overall, more than 25 different mutations in
MFN2 have been observed up to now in patients with
CMT2A, but also HMSN V and HMSN VI. There is cur-
rently no explanation for the divergence of phenotypes
associated with mutations in MFN2 [5]. Many mutations
are predicted to affect the GTPase domain of the protein,
but an equal proportion has been detected for the region
linking the GTPase domain and the first coiled coil region
(see fig. 2). The mutations described up to now seem to
cluster in several hotspot regions (aa94, aa236–251,
aa273–284, aa357–364), but we have not found any
recurrent mutation.
Five out of six mutations described in this paper are mis-
sense mutations, like the majority of mutations detected
in MFN2 up to now [5-8]. Of the five missense mutations,
one (G127V) affects the GTPase domain, and two muta-
tions change the region linking the GTPase domain and
the first coiled coil region (E347V and M376I). The two
other missense mutations (R468H and V705I) are pre-
dicted to cause amino acid substitutions between the
transmembrane domain and the coiled coil regions (fig.
2).
The missense mutation c.1403G→ A (R468H) is the first
described in the region between the transmembrane
domain and the C-terminal coiled coil region, and was
detected in patient 4 and her symptomatic father, indicat-
ing cosegregation of mutation and disease. The same sub-
stitution was detected in one out of 130 anonymous
control samples given by blood donors of different ages
assumed to be healthy. Since mild symptoms of CMT2
Structure of the MFN2 protein, showing functional domains and published mutations Figure 2
Structure of the MFN2 protein, showing functional domains and published mutations. Mutations described in this paper are 
underlined. Mutations associated with HMSN V and HMSN VI are marked with + and *, respectively.
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may have been missed in a younger blood donor added to
the control collective, this does not exclude the substition
R468H as pathogenic, but it may also represent a rare
sequence variant. Molecular biological studies may be
necessary to finally determine the nature of this substitu-
tion.
Another novel mutation (c.1040A>T) found in patient 3
in our series causes the change of the polar glutamine to
the non-polar valine at position 347. This amino acid
exchange occurred in a highly conserved region of MFN2.
This region is one of the indispensable segment of the pro-
tein that might provides binding sites for the assembly
[18].
Only one stop mutation, R418X, has been described
recently in a patient with CMT6 [9]. Interestingly, the
frameshift mutation c.2258_2259insT in our patient 6
would result in a protein only differing by four amino
acids and an extension of further five new amino acids at
the C-terminus of the protein. This mutation may affect
the C-terminal coiled-coil domain at the end of the fzo-
mitofusin domain. Analysis of MFN2 deletion constructs
revealed that GTPase-dependent interaction between the
N-terminal and C-terminal tails of MFN2 through their
coiled-coil domains and a highly conserved domain in the
most N-terminal region is essential for mitochondrial
fusion [18]. On the other hand it has been suggested that
the C-terminus of MFN2 contains determinants required
for targeting of the protein to the mitochondrial mem-
brane [20].
Further studies of promoter domains in the MFN2 gene
will help to clarify if these regions are involved in the
development of CMT2.
Conclusion
We confirmed a significant role of mutations in MFN2 in
the pathogenesis of Charcot-Marie-Tooth disease type 2.
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